Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study
Meijiao Zhou, Despina Ruessmann, Linda H. Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger · 2026
Read Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study by Meijiao Zhou, Despina Ruessmann, Linda H. Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13563778.txt.
Description
Meijiao Zhou and five colleagues track what happens in real clinics when dialysis patients start patiromer, a powder that binds potassium in the gut. High potassium threatens the hearts of people on haemodialysis, yet proof for this drug in that group was thin. Their 2026 study followed 10,860 adults at Fresenius clinics who began the drug between 2016 and 2022, comparing the three months before starting with a year after. Most took the lowest dose once daily, and dose changes were rare.
Control improved markedly: the share of patients below the 5.5 safety line rose from 35.6 to 69.9 percent, and average potassium settled from 5.60 down near 5.21 units by the fourth quarter. Use of the lowest-potassium dialysis fluid fell away as the drug took over. Hospital visits dipped for all causes and more for potassium crises. With no comparison group, the authors read the hospital trend cautiously, while calling the potassium control solid.
Catalog record
| CREATOR | Meijiao Zhou, Despina Ruessmann, Linda H. Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42170 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |